Cot inhibitor-2 | COT/Tpl2 抑制剂 | MCE

来自 : www.medchemexpress.cn/Cot-inhi 发布时间：2021-03-24

Cot inhibitor-2 (compound 34) is orally administered in rats with 100 mg/kg dosing and showed a Cmax of 517 ng/mL (0.89 μM) and AUC of 4841 ng•h/mL. Cot inhibitor-2 is tested in the LPS-induced TNF-α production model in female Sprague-Dawley rats. With a 25 mg/kg po dose, Cot inhibitor-2 inhibits LPS-induced TNF-α production by 83%[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cot inhibitor-2 是一种有效的,选择性的,具有口服活性的 cot (Tpl2/MAP3K8) 抑制剂,IC50 为 1.6 nM。Cot inhibitor-2 抑制 LPS 刺激的人全血中 TNF-α ...Cot inhibitor-2 | Cot inhibitor2 | Cot inhibitor 2 | MAP3K | MAP kinase kinase kinase, MEKK, MAPKKK | Tpl2 | cot | MAP3K8 | whole | blood | TNF-α | LPS | Inhibitor | inhibitor | inhibitCot inhibitor-2 是一种有效的，选择性的，具有口服活性的 cot (Tpl2/MAP3K8) 抑制剂，IC50 为 1.6 nM。Cot inhibitor-2 抑制 LPS 刺激的人全血中 TNF-α 的产生，IC50 为 0.3 μM。- 高纯度，全球文献引用。Cot inhibitor